410957
3-Isobutyl-1-methylxanthine
≥98% (HPLC), solid, cAMP and cGMP phosphodiesterase inhibitor, Calbiochem®
別名:
3-Isobutyl-1-methylxanthine, IBMX
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C10H14N4O2
CAS番号:
分子量:
222.24
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
製品名
3-Isobutyl-1-methylxanthine, A cell-permeable, non-specific inhibitor of cAMP and cGMP phosphodiesterases (IC50 = 2-50 µM).
SMILES string
[n]1(c2nc[nH]c2[c]([n]([c]1=O)C)=O)CC(C)C
InChI
1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)
InChI key
APIXJSLKIYYUKG-UHFFFAOYSA-N
description
RTECS - ZD8500000
assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white
solubility
ethanol: 10 mg/mL, DMSO: 100 mM, methanol: 50 mg/mL
shipped in
ambient
storage temp.
−20°C
Quality Level
General description
A cell-permeable, non-specific inhibitor of cAMP and cGMP phosphodiesterases (IC50 = 2-50 µM). Also acts as an adenosine receptor antagonist. Reported to inhibit TNF-α expression in adipocyte precursor cells.
A non-specific, cell-permeable inhibitor of cAMP and cGMP phosphodiesterases (IC50 = 2-50 µM). Also acts as an adenosine receptor antagonist. Reported to inhibit TNFα expression in adipocyte precursor cells.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
cAMP and cGMP phosphodiesterases
cAMP and cGMP phosphodiesterases
Product does not compete with ATP.
Reversible: no
Target IC50: 2-50 µM against cAMP and cGMP phosphodiesterases
Preparation Note
Following reconstitution in ethanol or methanol, refrigerate (4°C). Following reconstitution in DMSO, aliquot and freeze (-20°C). Ethanol/methanol and DMSO stock solutions are stable for up to 6 months at 4°C or -20°C, respectively.
Heating may be required to achieve complete solubilization.
Other Notes
Hube, F., et al. 1999. Horm. Metab. Res.31, 359.
Morgan, A.J., et al. 1993. Biochem. Pharmacol.45, 2373.
Scamps, F., et al. 1993. Eur. J. Pharmacol. 244, 119.
Turner, N.C., et al. 1993. Br. J. Pharmacol. 108, 876.
Tamura, T., et al. 1991. J. Gen. Physiol. 98, 95.
Beavo, J.A., and Reifsnyder, D.H. 1990. Trends Pharmacol. Sci.11, 150.
Russell, T.R. 1979. Proc. Natl. Acad. Sci. USA76, 4451.
Morgan, A.J., et al. 1993. Biochem. Pharmacol.45, 2373.
Scamps, F., et al. 1993. Eur. J. Pharmacol. 244, 119.
Turner, N.C., et al. 1993. Br. J. Pharmacol. 108, 876.
Tamura, T., et al. 1991. J. Gen. Physiol. 98, 95.
Beavo, J.A., and Reifsnyder, D.H. 1990. Trends Pharmacol. Sci.11, 150.
Russell, T.R. 1979. Proc. Natl. Acad. Sci. USA76, 4451.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
410957-MG: + 410957-250MG: + 410957-1GM: + 410957-1.1ML:
jan
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Dina Hany et al.
Science advances, 9(19), eadd3685-eadd3685 (2023-05-12)
In breast cancer, resistance to endocrine therapies that target estrogen receptor α (ERα), such as tamoxifen and fulvestrant, remains a major clinical problem. Whether and how ERα+ breast cancers switch from being estrogen-dependent to estrogen-independent remains unclear. With a genome-wide
H Ji
Methods in molecular medicine, 51, 363-377 (2001-01-01)
Angiotensin type-1 receptors (AT(1) receptors) mediate various physiological actions of angiotensin (Ang II) via multiple-signal transduction pathways (1). In addition to the phospholipase C pathway and dihydropyridine-sensitive voltage-dependent calcium channels, AT(1) receptors can couple to inhibition of adenylate cyclase via
Jiankun Xu et al.
Bioactive materials, 8, 95-108 (2021-09-21)
Magnesium metal and its alloys are being developed as effective orthopedic implants; however, the mechanisms underlying the actions of magnesium on bones remain unclear. Cystic fibrosis, the most common genetic disease in Caucasians caused by the mutation of CFTR, has
Jiang Li et al.
Antioxidants (Basel, Switzerland), 13(5) (2024-05-25)
Hypertension reduces the bioavailability of vascular nitric oxide (NO) and contributes to the onset of vascular dementia (VaD). A loss of NO bioavailability increases inflammation and oxidative stress. 2-(4-Methylthiazol-5-yl) ethyl nitrate hydrochloride (W1302) is a novel nitric oxide donor (NOD)
Thijs Roebroek et al.
Nature communications, 12(1), 2005-2005 (2021-04-02)
Förster resonant energy transfer (FRET) is a powerful mechanism to probe associations in situ. Simultaneously performing more than one FRET measurement can be challenging due to the spectral bandwidth required for the donor and acceptor fluorophores. We present an approach
グローバルトレードアイテム番号
| カタログ番号 | GTIN |
|---|---|
| 410957-250MGCN | 04055977211146 |
| 410957-1GMCN | 04055977211139 |
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）